Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...

Its growth is attributed to the anticipated launch of seven late-stage pipeline therapies. The myasthenia gravis (MG) market ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

SCOTTSDALE, Ariz. — June 16, 2025 — The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those ...

The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the ...

A drug targeting immunoglobulin G (IgG) currently approved for myasthenia gravis and chronic inflammatory demyelinating ...

During last Monday’s meeting, the Matagorda County Commissioners Court proclaimed June as Myasthenia Gravis Awareness Month, ...

Efgartigimod (Vyvgart) is not normally available on the NHS as an add-on to standard treatment for generalised myasthenia gravis in adults who test positive for anti-acetylcholine receptor antibodies.

Efgartigimod (Vyvgart, Argenx) is indicated as 'an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New Jersey drugmaker is confident that a broad label will land its product an ...

The drug is the “first and only” human Fc receptor (FcRn)-blocking monoclonal antibody approved by ... as measured by the Myasthenia Gravis-Activities of Daily Living (MG-ADL) assessment ...